Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study

J Am Coll Cardiol. 2002 Apr 3;39(7):1133-8. doi: 10.1016/s0735-1097(02)01728-x.


Objectives: The goal of this study was to assess soluble intercellular adhesion molecule-1 (sICAM-1) level as a predictor of future acute coronary events in patients with chronic coronary heart disease (CHD).

Background: Increased sICAM-1 concentration has been shown to be associated with the incidence of CHD in healthy persons. Its significance in patients with CHD has been scarcely investigated.

Methods: We designed a prospective, nested case-control study. Sera were collected from patients with CHD enrolled in a secondary prevention trial that evaluated the efficacy of bezafibrate in reducing coronary events. We measured baseline sICAM-1 concentration in the sera of patients who developed subsequent cardiovascular events (cases: n = 136) during follow-up (mean: 6.2 years) and in age- and gender-matched controls (without events: n = 136).

Results: Baseline serum concentrations of sICAM-1 were significantly higher in cases versus controls (375 vs. 350 ng/ml; p < 0.05). Each 100 ng/ml increase in sICAM-1 concentration was associated with 1.27 (95% confidence interval [CI]: 1.00 to 1.63) higher relative odds of coronary events. Soluble ICAM-1 concentration in the highest quartile (>394 ng/ml) was associated with significantly higher odds of coronary events (compared with the lowest quartile), even after multivariate adjustment (2.31, 95% CI: 1.02 to 5.50). After adding fibrinogen and total white blood cell count to the multivariate model, the relative odds were 2.12 (95% CI: 0.88 to 5.35) and 2.70 (95% CI: 1.10 to 7.05), respectively.

Conclusions: Elevated sICAM-1 concentration in CHD patients is associated with increased risk of future coronary events independent of other traditional risk factors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bezafibrate / therapeutic use*
  • Case-Control Studies
  • Coronary Disease / blood*
  • Coronary Disease / epidemiology
  • Female
  • Follow-Up Studies
  • Humans
  • Hypolipidemic Agents / therapeutic use*
  • Intercellular Adhesion Molecule-1 / blood*
  • Logistic Models
  • Male
  • Middle Aged
  • Myocardial Infarction / prevention & control
  • Prospective Studies
  • Risk Assessment
  • Time Factors


  • Hypolipidemic Agents
  • Intercellular Adhesion Molecule-1
  • Bezafibrate